{"id":47845,"date":"2022-08-31T14:02:12","date_gmt":"2022-08-31T12:02:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/"},"modified":"2022-08-31T14:02:12","modified_gmt":"2022-08-31T12:02:12","slug":"novocure-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Novocure to Participate in Upcoming Investor Conferences"},"content":{"rendered":"
\n

ROOT, Switzerland–(BUSINESS WIRE)–$NVCR<\/a>–Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure\u2019s website, www.novocure.com\/investor-relations<\/a>, and will be available for replay for at least 14 days following the event.\n<\/p>\n

<\/a><\/p>\n

\nMs. Cordova will be joined by Dr. Ely Benaim, Chief Medical Officer, for additional one-on-one meetings with investors as part of the H.C. Wainwright 24th<\/sup> Annual Global Investment Conference on September 13, 2022.\n<\/p>\n

\nNovocure\u2019s corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure\u2019s website, www.novocure.com\/investor-relations<\/a>. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.\n<\/p>\n

\nAbout Novocure<\/b>\n<\/p>\n

\nNovocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure\u2019s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.\n<\/p>\n

\nHeadquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nIn addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure\u2019s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as \u201canticipate,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve\u201d or other words and terms of similar meaning. Novocure\u2019s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 24, 2022, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Ingrid Goldberg
\n
investorinfo@novocure.com<\/a>
610-723-7427\n<\/p>\n

\nMedia:<\/b>
Leigh Labrie
\n
media@novocure.com<\/a>
610-723-7428\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROOT, Switzerland–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47845","6":"format-standard","7":"category-industry"},"yoast_head":"\nNovocure to Participate in Upcoming Investor Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novocure to Participate in Upcoming Investor Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROOT, Switzerland–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-31T12:02:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220831005073\/en\/721126\/21\/novocure_main%405x.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Novocure to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2022-08-31T12:02:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":596,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220831005073\\\/en\\\/721126\\\/21\\\/novocure_main%405x.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Novocure to Participate in Upcoming Investor Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220831005073\\\/en\\\/721126\\\/21\\\/novocure_main%405x.jpg\",\"datePublished\":\"2022-08-31T12:02:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220831005073\\\/en\\\/721126\\\/21\\\/novocure_main%405x.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220831005073\\\/en\\\/721126\\\/21\\\/novocure_main%405x.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novocure-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novocure to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novocure to Participate in Upcoming Investor Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Novocure to Participate in Upcoming Investor Conferences - Pharma Trend","og_description":"ROOT, Switzerland–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-31T12:02:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220831005073\/en\/721126\/21\/novocure_main%405x.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Novocure to Participate in Upcoming Investor Conferences","datePublished":"2022-08-31T12:02:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/"},"wordCount":596,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220831005073\/en\/721126\/21\/novocure_main%405x.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/","name":"Novocure to Participate in Upcoming Investor Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220831005073\/en\/721126\/21\/novocure_main%405x.jpg","datePublished":"2022-08-31T12:02:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220831005073\/en\/721126\/21\/novocure_main%405x.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220831005073\/en\/721126\/21\/novocure_main%405x.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/novocure-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Novocure to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47845"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47845\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}